Literature DB >> 8827361

p53 is frequently mutated in Barrett's metaplasia of the intestinal type.

P Campomenosi1, M Conio, M Bogliolo, S Urbini, P Assereto, A Aprile, P Monti, H Aste, G Lapertosa, A Inga, A Abbondandolo, G Fronza.   

Abstract

Barrett's Esophagus (BE) is a complication of gastroesophageal reflux in which the normal squamous epithelium of the lower esophagus is replaced by metaplastic tissue. The clinical significance of this condition is the associated predisposition to adenocarcinomas (ADCs). Three types of BE have been characterized: the gastric fundic (F) type, the gastric cardial (C) type, and the intestinal (I) type. The latter is the most closely associated with the development of ADCs; the causes of this bias remain unknown. To determine whether p53 and/or K-ras gene alterations (a) are present in preneoplastic lesions and (b) are associated with a specific histotype, we performed PCR-based denaturing gradient gel electrophoresis (DGGE) analysis of exon 1 (codons 12-13) of K-ras gene and of exons 5-8 of the p53 gene in biopsies obtained from 30 patients with BE of the I type (9 patients), combined I type (I + C +/- F; 10 patients) and non-I type (C, F, or C + F; 11 patients). None of the cases under study revealed K-ras mutations, whereas biopsies from 12 patients showed at least one p53 DGGE variant. Four patients showed the exact same variants in leukocytes also (polymorphisms), whereas eight cases revealed specific DGGE variants only in biopsies. The molecular characterization of these variants revealed that four of them showed a single base pair substitution, and four showed multiple mutations. Of 17 somatic mutations, all but 1 were base pair substitutions located mainly in exons 7 and 8. The majority of these mutations were GC targeted (13 of 16; 81%), 54% (7 of 13) of which were transitions occurring at CpG sites. All somatic mutations were found in BE with at least one I component. The association with the histotype was statistically significant (P < 0.03; pure I type versus non-I type; P < 0.04, combined I type versus non-I type; Fisher's exact test). Loss of heterozygosity in the vicinity of the p53 locus was evaluated by PCR using a highly polymorphic variable number of tandem repeats marker on 25 out of 30 cases. Ninety-two % of the cases analyzed were informative, and none of them showed LOH. In conclusion, we showed that p53 mutations are frequently observed in specimens from BE patients of the I-type, whereas no involvement of K-ras (exon 1) mutational activation was observed. In light of the key roles that the p53 protein plays in controlling cell cycle and cell diploidy, this result may suggest why this type of metaplasia is the most closely associated to the development of ADCs.

Entities:  

Mesh:

Year:  1996        PMID: 8827361

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  13 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

3.  Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma.

Authors:  Nishant Agrawal; Yuchen Jiao; Chetan Bettegowda; Susan M Hutfless; Yuxuan Wang; Stefan David; Yulan Cheng; William S Twaddell; Nyan L Latt; Eun J Shin; Li-Dong Wang; Liang Wang; Wancai Yang; Victor E Velculescu; Bert Vogelstein; Nickolas Papadopoulos; Kenneth W Kinzler; Stephen J Meltzer
Journal:  Cancer Discov       Date:  2012-08-09       Impact factor: 39.397

Review 4.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

Review 5.  Diagnosis and grading of dysplasia in Barrett's oesophagus.

Authors:  R D Odze
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

6.  Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.

Authors:  A P Ireland; D K Shibata; P Chandrasoma; R V Lord; J H Peters; T R DeMeester
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

Review 7.  Pathology of gallbladder carcinoma: current understanding and new perspectives.

Authors:  Munita Meenu Bal; Mukta Ramadwar; Kedar Deodhar; Shailesh Shrikhande
Journal:  Pathol Oncol Res       Date:  2015-01-25       Impact factor: 3.201

8.  p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.

Authors:  A G Casson; M Tammemagi; S Eskandarian; M Redston; J McLaughlin; H Ozcelik
Journal:  Mol Pathol       Date:  1998-04

9.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 10.  Barrett's esophagus: model of neoplastic progression.

Authors:  Stig Ramel
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.